- Pfizer (NYSE:PFE) announces positive results from a Phase 2a clinical trial evaluating JAK3 inhibitor PF-06651600 and TYK2/JAK1 inhibitor PF-06700841 in patients with moderate-to-severe alopecia areata (AA), an autoimmune disorder characterized by hair loss. The data were presented the EADV Congress in Paris.
- Both candidates demonstrated statistically significant treatment effects (hair regrowth at week 24 versus baseline as measured by a 100-point scale called SALT score) compared to placebo. Specifically, average SALT scores for patients receiving the JAK3 inhibitor and TYK2/JAK1 inhibitor were 33.6 and 49.5, respectively, on a placebo-adjusted basis (both p values were less than 0.0001).
- All secondary endpoints were also met.
- On the safety front, the categories of the most common adverse events were infections, gastrointestinal and skin/subcutaneous tissue. There were no cases of herpes zoster reactivation.
- The company plans to advance Breakthrough Therapy-tagged PF-06651600 into Phase 3 development for AA and will continue to evaluate it in rheumatoid arthritis, Crohn's, and ulcerative colitis (UC). PF-06700841 will continue to be assessed in Crohn's, psoriasis and UC.
- Now read: Stocks To Watch: Oracle (NYSE:ORCL) Looks To Lift Tech Sector
Original article